Jenkins William S, Roger Véronique L, Jaffe Allan S, Weston Susan A, AbouEzzeddine Omar F, Jiang Ruoxiang, Manemann Sheila M, Enriquez-Sarano Maurice
Division of Cardiovascular Diseases in the Department of Internal Medicine, Mayo Clinic, Rochester, Minn.
Division of Cardiovascular Diseases in the Department of Internal Medicine, Mayo Clinic, Rochester, Minn; Department of Health Sciences Research, Mayo Clinic, Rochester, Minn.
Am J Med. 2017 Sep;130(9):1112.e9-1112.e15. doi: 10.1016/j.amjmed.2017.02.034. Epub 2017 Mar 23.
Soluble ST2 (sST2) is a marker of cardiac mechanical strain hypothesized to adversely impact short-term prognosis after myocardial infarction. We examined the association of sST2 with longer-term outcomes after myocardial infarction in a geographically defined community.
Olmsted County, Minnesota residents who experienced an incident (first-ever) myocardial infarction between November 1, 2002 and December 31, 2012 were prospectively enrolled; sST2 levels were measured. Patients were followed for heart failure and death.
We studied 1401 patients with incident myocardial infarction (mean age 67 years; 61% men; 79% non-ST-elevation myocardial infarction). Median sST2 (ng/mL) was 48.7 (25-75 percentile 32.5-103.3). Soluble ST2 was elevated in 51% of patients. Higher values of sST2 were associated with increased age, female sex, and comorbidities. During 5 years of follow-up, 388 persons died and 360 developed heart failure. After adjustment for age, sex, comorbidities, Killip class, and troponin T, the hazard ratios for death were 1.73 (95% confidence interval [CI], 1.22-2.45) and 3.57 (95% CI, 2.57-4.96) for sST2 tertiles 2 and 3, respectively (P <.001). For heart failure, the hazard ratios were 1.67 (95% CI, 1.18-2.37) and 2.88 (95% CI, 2.05-4.05), respectively (P <.001). Results were similar among 30-day survivors.
In the community, sST2 elevation is present in half of myocardial infarctions. Higher values of sST2 are associated with a large excess risk of death and heart failure independently of other prognostic indicators. Measurement of sST2 should be considered for risk stratification after myocardial infarction.
可溶性ST2(sST2)是一种心脏机械应变标志物,据推测会对心肌梗死后的短期预后产生不利影响。我们在一个地理区域明确的社区中研究了sST2与心肌梗死后长期预后的关联。
前瞻性纳入了2002年11月1日至2012年12月31日期间首次发生心肌梗死的明尼苏达州奥姆斯特德县居民;测量了sST2水平。对患者进行心力衰竭和死亡随访。
我们研究了1401例首次发生心肌梗死的患者(平均年龄67岁;61%为男性;79%为非ST段抬高型心肌梗死)。sST2的中位数(ng/mL)为48.7(四分位数间距25 - 75为32.5 - 103.3)。51%的患者sST2升高。sST2值越高与年龄增加、女性及合并症相关。在5年随访期间,388人死亡,360人发生心力衰竭。在调整年龄、性别、合并症、Killip分级和肌钙蛋白T后,sST2三分位数2和3的死亡风险比分别为1.73(95%置信区间[CI],1.22 - 2.45)和3.57(95%CI,2.57 - 4.96)(P <.001)。对于心力衰竭,风险比分别为1.67(95%CI,1.18 - 2.37)和2.88(95%CI,2.05 - 4.05)(P <.001)。30天幸存者的结果相似。
在该社区中,一半的心肌梗死患者sST2升高。sST2值越高与死亡和心力衰竭的大量额外风险相关,独立于其他预后指标。心肌梗死后风险分层应考虑检测sST2。